Information and calculation tools by Rachid Asen. Not investment advice or research.

Disclaimer. Information tool. Compiles data published by NSE and BSE and calculations from the exchanges' published ESM and ASM criteria. Prices are end-of-day, not live: updated each evening after trading ends. Ethical business criteria are matched by AI, which can make mistakes; this is a criteria match, not a certification, fatwa, rating or advice. Check the company's filings. Not investment advice, research or a recommendation to buy, sell or hold any security; not SEBI-registered as an Investment Adviser or Research Analyst. Calculated dates are the earliest a security could become eligible; inclusion, stage changes and exit are decided solely by the exchanges. ESM, ASM and GSM shortlisting are surveillance measures and not an adverse action against the company. Data may be delayed or inaccurate; verify with the exchange.

SurveillanceLabby Rachid AsenSupportSign in
Market closedPro tools are for Pro members only. Pro access requires signing an NDA.Pro needs an NDA.Request Pro accessRequest accessIST

Fredun Pharmaceuticals Limited

FREDUN (NSE) · FREDUN (BSE 539730) · ISIN INE194R01017 · Pharmaceuticals · Est. 1987 · listed 2026 · website

Not on any surveillance list

In Q1 FY27 (quarter to 30 June 2026, standalone), revenue was ₹227.76 cr and profit after tax ₹13.17 cr. Revenue was 90.8% higher than in Q1 FY26.

Open the full company file Every section, filings and your notes, in the app.

Quarterly results

Quarterly results, ₹ crore (as filed)
QuarterRevenueProfit after taxEPS (₹)Filed
Q1 FY27 standalone₹227.76 cr₹13.17 cr22.255 Aug 2026
Q4 FY26 standalone₹210.41 cr₹11.07 cr18.7025 May 2026
Q3 FY26 standalone₹159.93 cr₹10.48 cr17.7114 Feb 2026
Q2 FY26 standalone₹143.59 cr₹9.73 cr20.619 Nov 2025
Q1 FY26 standalone₹119.4 cr₹6.77 cr14.3330 Jul 2025

Balance sheet

Balance sheet, ₹ crore (as filed)
As ofTotal equityBorrowingsTotal assets
31 Mar 2026 standalone₹278.71 cr₹222.03 cr₹642.14 cr
30 Sep 2025 standalone₹157.57 cr₹170.68 cr₹464.09 cr
31 Mar 2025 standalone₹141.4 cr₹166.41 cr₹486.65 cr

Other companies in Pharmaceuticals

Figures as filed by the company with NSE and BSE; surveillance status from the exchanges' lists. Updated 5 August 2026.

Information and calculation tools by Rachid Asen. Not investment advice or research. Facts from company filings and the exchanges' lists, for information only; not a recommendation to buy, sell or hold. Verify with the exchange.